ACRS
Aclaris Therapeutics, Inc.
+0.21 (+3.85%)5.53USD2.2M成交股數813M市值–本益比(近四季)99.0股價營收比-8.3%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.6M+12% | 2.0M-78% | 3.3M-24% | 1.8M-36% | 1.5M-39% | 9.2M-1% | 4.3M+133% | 2.8M+9% | 2.4M | 9.3M | 1.9M | 2.5M |
| 營業成本 | 218K | 395K | 538K | 515K | 506K | 705K | 654K | 624K | 809K | 848K | 1.0M | 808K |
| 毛利 | 1.4M+49% | 1.6M-81% | 2.8M-25% | 1.3M-41% | 949K-40% | 8.5M+1% | 3.7M+346% | 2.1M+25% | 1.6M | 8.4M | 827K | 1.7M |
| 毛利率 | 86.6% | 80.2% | 83.7% | 71.0% | 65.2% | 92.3% | 85.0% | 77.4% | 66.3% | 90.9% | 44.2% | 68.0% |
| 研發費用 | 18.1M | 15.7M | 13.0M | 11.4M | 11.6M | 9.0M | 6.0M | 8.8M | 9.8M | 23.9M | 25.3M | 22.6M |
| 銷售管理費用 | 6.0M | 6.7M | 4.9M | 5.4M | 6.1M | 5.0M | 5.7M | 4.8M | 6.8M | 7.1M | 8.3M | 8.8M |
| 營業利益 | −24.2M+34% | −22.2M-78% | −17.1M+64% | −18.4M+43% | −18.1M-4% | −99.7M+216% | −10.5M-67% | −12.9M-57% | −18.9M | −31.6M | −31.8M | −29.9M |
| 營業利益率 | -1,487.9% | -1,111.8% | -519.8% | -1,035.9% | -1,242.9% | -1,082.3% | -240.9% | -464.7% | -789.4% | -340.2% | -1,702.2% | -1,183.5% |
| 稅後淨利 | −21.5M+43% | −19.8M-79% | −14.6M+93% | −15.4M+40% | −15.1M-11% | −96.6M+230% | −7.6M-74% | −11.0M-61% | −16.9M | −29.3M | −29.6M | −28.2M |
| 淨利率 | -1,320.1% | -993.2% | -443.0% | -868.3% | -1,036.8% | -1,048.3% | -174.6% | -397.2% | -706.5% | -315.2% | -1,582.1% | -1,113.9% |
| 稀釋 EPS | -0.15+25% | -0.15-88% | -0.12+9% | -0.13-13% | -0.12-50% | -1.21+195% | -0.11-74% | -0.15-64% | -0.24 | -0.41 | -0.42 | -0.42 |
| 稀釋股數 | 143M | 129M | 123M | 123M | 122M | 77.3M | 71.4M | 71.3M | 71.1M | 70.8M | 70.6M | 66.9M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 19.2M | 28.7M | 25.3M | 25.4M | 30.4M | 24.6M | 47.7M | 22.8M | 35.8M | 39.0M | 31.2M | 44.7M |
| 應收帳款 | – | – | – | 194K | 250K | 318K | 343K | 325K | 373K | 346K | 431K | 686K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 180M | 199M | 176M | 189M | 198M | 220M | 182M | 161M | 174M | 218M | 236M | 230M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 55.1M | 55.1M | 55.4M | 57.4M | 54.0M | 64.8M | 52.2M | 27.2M | 32.1M | 62.0M | 55.9M | 52.9M |
| 股東權益 | 125M | 144M | 120M | 132M | 144M | 156M | 130M | 134M | 142M | 156M | 180M | 177M |
| 負債比 | 30.7% | 27.7% | 31.6% | 30.4% | 27.3% | 29.4% | 28.6% | 16.9% | 18.4% | 28.4% | 23.7% | 23.0% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −18.1M | – | – | −13.1M-37% | – | – | – | −20.8M | – | – | −26.4M |
| 資本支出 | – | 13K | – | – | 43K | – | – | – | 135K | – | – | 553K |
| 自由現金流 | – | −18.2M | – | – | −13.1M-37% | – | – | – | −21.0M | – | – | −26.9M |
| 折舊攤銷 | – | 102K | – | – | 128K | – | – | – | 243K | – | – | 198K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -909.9% | – | – | -900.3% | – | – | – | -873.6% | – | – | -1,064.3% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 7.8M
| Single Reportable | 7.8M | 100.0% | -58.2% |
|---|
產品／服務2025 年度 · 7.8M
| License And Service | 6.0M | 76.1% | -63.2% |
|---|---|---|---|
| Laboratory Research Revenue | 1.9M | 23.9% | -26.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 7.8M | -58.2% | −64.9M | -829.6% | -0.53 | −47.2M |
| FY2024 | 18.7M | -40.1% | −132M | -705.5% | -1.71 | −20.2M |
| FY2023 | 31.2M | +5.0% | −88.5M | -283.1% | -1.27 | −79.6M |
| FY2022 | 29.8M | +340.1% | −86.9M | -292.1% | -1.33 | −68.2M |
| FY2021 | 6.8M | +4.3% | −90.9M | -1,344.0% | -1.60 | −52.4M |
| FY2020 | 6.5M | +53.3% | −51.0M | -787.0% | -1.20 | −39.1M |
| FY2019 | 4.2M | -31.3% | −161M | -3,817.2% | -3.90 | −98.1M |
| FY2018 | 6.2M | – | −133M | -2,158.0% | -4.03 | −102M |